A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, J. P.; Yerly Ferrillo, Sabine; Bisset, L. R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Gunthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc

doi:10.1086/340312

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
Authors		Opravil, Milos Hirschel, Bernard Lazzarin, Adriano Furrer, Hansjakob Chave, J. P. Yerly Ferrillo, Sabine Bisset, L. R. Fischer, Marek Vernazza, Pietro Bernasconi, Enos Battegay, Manuel Ledergerber, Bruno Gunthard, Huldrych Howe, Colin Weber, Rainer Perrin, Luc show all authors [1 - 16]
Published in		The Journal of Infectious Diseases. 2002, vol. 185, no. 9, p. 1251-1260
Abstract		This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n=79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n=84) in patients with suppressed human immunodeficiency virus type 1 (HIV-1) RNA for > or = 6 months who did not have the reverse transcriptase 215 mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and 15% in the simplified group (P=.081). Previous zidovudine monotherapy or dual therapy and archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant predictors of failure. Study treatment was discontinued because of adverse events in 20% of the continuation and 7% of the simplified group (P=.021). Simplification to abacavir-lamivudine-zidovudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch strategy carries a risk of virologic failure when treatment history or resistance testing suggest the presence of archived resistance mutations to the simplified regimen.
Keywords		Acquired Immunodeficiency Syndrome/ drug therapy/metabolism/virology — Anti-HIV Agents/ administration & dosage — Dideoxynucleosides/ administration & dosage — Drug Therapy, Combination — Female — Hiv-1 — Humans — Lamivudine/ administration & dosage — Lipids/blood — Male — Prospective Studies — RNA, Viral/blood — Treatment Failure — Viral Load — Zidovudine/ administration & dosage
Identifiers		DOI: 10.1086/340312 PMID: 12001042
Full text		Article - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Citation (ISO format)		OPRAVIL, Milos et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. In: The Journal of Infectious Diseases, 2002, vol. 185, n° 9, p. 1251-1260. doi: 10.1086/340312 https://archive-ouverte.unige.ch/unige:7451